Accueil>>Signaling Pathways>> Microbiology & Virology>> Bacterial>>Erythromycin

Erythromycin (Synonyms: NSC 55929)

Catalog No.GC12946

L'érythromycine est un antibiotique macrolide produit par l'actinomycète Streptomyces erythreus avec un large spectre d'activité antimicrobienne.

Products are for research use only. Not for human use. We do not sell to patients.

Erythromycin Chemical Structure

Cas No.: 114-07-8

Taille Prix Stock Qté
10mM (in 1mL DMSO)
27,00 $US
En stock
500mg
25,00 $US
En stock
1g
29,00 $US
En stock
5g
44,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Erythromycin is a macrolide antibiotic produced by actinomycete Streptomyces erythreus with a broad spectrum of antimicrobial activity. Erythromycin acts by binding to bacterial 50S ribosomal subunits and inhibits RNA-dependent protein synthesis by blockage of transpeptidation and/or translocation reactions, without affecting synthesis of nucleic acid[1].

Erythromycin inhibits growth of P. falciparum with IC50 and IC90 values of 58.2 μM and 104.0 μM, respectively[1].

References:
[1]. Gribble MJ, et al. Erythromycin. Med Clin North Am. 1982 Jan;66(1):79-89.
[2]. Nakornchai S, et al. Activity of azithromycin or erythromycin in combination with antimalarial drugs against multidrug-resistant Plasmodium falciparum in vitro. Acta Trop. 2006 Dec;100(3):185-91. Epub 2006 Nov 28.

Avis

Review for Erythromycin

Average Rating: 5 ★★★★★ (Based on Reviews and 8 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Erythromycin

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.